[Immunochemotherapy of recurrent and advanced uterine and ovarian cancer using cisplatin].
A combination immunochemotherapy regimen containing cisplatin (20 mg, days 1-5), peplomycin (20 mg, days 2, 9, 16), +/- vinblastine (5 mg, days 1, 2), and picibanil (3-5 KE/week) was performed in twelve patients with advanced or recurrent uterine and ovarian cancers under intravenous hyperalimentation (IVH), except one patient receiving peplomycin by a continuous infusion method using IVH bag (10 mg/day for 5 days). This regimen was repeated every three weeks. Five (71.4%) of seven evaluable patients showed partial response. No patients yielded the complete disappearance of disease. No severe and lethal pulmonary or renal dysfunction occurred and all was well tolerated. In a regimen without vinblastine, myelosuppression, especially thrombocytopenia, occurred later compared to the regimen including vinblastine.
D000230:Adenocarcinoma / Q000628:therapy*; D000368:Aged; D001688:Biological Products / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy*; D017663:Peplomycin; D010844:Picibanil / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000628:therapy; D014594:Uterine Neoplasms / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage
D001688:Biological Products; D001761:Bleomycin; D010844:Picibanil; D017663:Peplomycin; D014747:Vinblastine; D002945:Cisplatin